Technical Analysis for CBLI - Cleveland BioLabs, Inc.

Grade Last Price % Change Price Change
grade C 1.62 -2.99% -0.05
CBLI closed down 2.99 percent on Friday, March 22, 2019, on 73 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical CBLI trend table...

Date Alert Name Type % Chg
Mar 22 Doji - Bullish? Reversal 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 Bearish Engulfing Bearish -2.99%
Mar 21 Wide Bands Range Expansion -2.99%
Mar 20 Wide Bands Range Expansion -4.71%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 18 1,2,3 Pullback Bullish Bullish Swing Setup -7.95%
Mar 18 180 Bullish Setup Bullish Swing Setup -7.95%

Older signals for CBLI ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Medicine Biotechnology Cancer Clinical Medicine Treatment Of Cancer Solid Tumors Chemotherapy Stem Cells Radiation Cancer Treatments Prostate Cancer Cancer Treatment Advanced Solid Tumors
Is CBLI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.44
52 Week Low 1.0
Average Volume 11,193
200-Day Moving Average 1.8595
50-Day Moving Average 1.4743
20-Day Moving Average 1.5437
10-Day Moving Average 1.6963
Average True Range 0.1637
ADX 34.3
+DI 27.1116
-DI 12.3663
Chandelier Exit (Long, 3 ATRs ) 1.6689
Chandelier Exit (Short, 3 ATRs ) 1.6911
Upper Bollinger Band 2.0266
Lower Bollinger Band 1.0608
Percent B (%b) 0.58
BandWidth 62.56397
MACD Line 0.0717
MACD Signal Line 0.0695
MACD Histogram 0.0022
Fundamentals Value
Market Cap 18.27 Million
Num Shares 11.3 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -2.42
Price-to-Sales 12.32
Price-to-Book 7.79
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.83
Resistance 3 (R3) 1.84 1.78 1.80
Resistance 2 (R2) 1.78 1.73 1.78 1.78
Resistance 1 (R1) 1.70 1.69 1.67 1.69 1.77
Pivot Point 1.64 1.64 1.63 1.64 1.64
Support 1 (S1) 1.56 1.59 1.53 1.55 1.47
Support 2 (S2) 1.50 1.55 1.50 1.46
Support 3 (S3) 1.42 1.50 1.45
Support 4 (S4) 1.41